AR Gene Androgen Insensitivity Partial with or without Breast Cancer NGS Genetic DNA Test
Comprehensive Genetic Analysis for Androgen Receptor Disorders
The AR Gene Androgen Insensitivity Partial with or without Breast Cancer NGS Genetic DNA Test represents a cutting-edge diagnostic approach for identifying mutations in the androgen receptor gene that can lead to partial androgen insensitivity syndrome and potentially increase breast cancer risk. This sophisticated genetic analysis utilizes next-generation sequencing technology to provide comprehensive insights into your genetic makeup, enabling early detection and personalized treatment strategies.
What This Advanced Genetic Test Measures
This comprehensive DNA test specifically targets the androgen receptor (AR) gene located on the X chromosome, analyzing it for various mutations including:
- Point mutations affecting androgen binding domains
- Deletions and insertions in the AR gene sequence
- Single nucleotide polymorphisms (SNPs) associated with partial androgen insensitivity
- Genetic variations linked to increased breast cancer susceptibility
- Mutations affecting androgen receptor function and signaling pathways
Who Should Consider This Genetic Testing
This test is particularly recommended for individuals experiencing:
- Ambiguous genitalia or atypical sexual development
- Primary amenorrhea in individuals with female external genitalia
- Infertility issues with normal male external genitalia
- Family history of androgen insensitivity disorders
- Unexplained breast development in genetic males
- Individuals with suspected partial androgen insensitivity syndrome
- Those with family history of early-onset breast cancer
- Patients with endocrine disorders affecting sexual development
Significant Benefits of Genetic Testing
Undergoing this comprehensive genetic analysis provides numerous advantages:
- Early Diagnosis: Enables timely identification of androgen receptor mutations
- Personalized Treatment: Guides hormone therapy and medical management decisions
- Family Planning: Provides crucial information for reproductive decisions
- Cancer Risk Assessment: Helps evaluate potential breast cancer susceptibility
- Psychological Relief: Reduces uncertainty about genetic conditions
- Preventive Care: Facilitates proactive health monitoring strategies
Understanding Your Test Results
Your genetic test results will be carefully interpreted by our expert genetic counselors and medical professionals. Positive results indicating AR gene mutations may suggest partial androgen insensitivity syndrome, which can affect hormone responsiveness and sexual development. Negative results typically indicate normal androgen receptor gene function. All results come with comprehensive explanations and recommendations for next steps, including potential referrals to endocrinology specialists and ongoing monitoring protocols.
Test Pricing and Availability
| Price Type | Amount (USD) |
|---|---|
| Discount Price | $500 |
| Regular Price | $700 |
Nationwide Testing Facilities
We have conveniently located branches across the United States, including major metropolitan areas such as New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, and San Jose. Our state-of-the-art facilities ensure comfortable testing experiences with professional genetic counseling services available at each location.
Take Control of Your Genetic Health Today
Don’t let uncertainty about genetic conditions affect your health decisions. Our AR Gene Androgen Insensitivity Partial with or without Breast Cancer NGS Genetic DNA Test provides the clarity you need for informed medical choices. With results available in 3-4 weeks and multiple sample collection options including blood, extracted DNA, or blood spots on FTA cards, getting tested has never been more convenient.
Call or WhatsApp us today at +1(267) 388-9828 to schedule your genetic counseling session and book your test. Our dedicated team is ready to guide you through every step of the process and help you understand your genetic health.
